Abstract Number: 2241 • 2017 ACR/ARHP Annual Meeting
Patterns and Outcomes on Disease Activity in Patients with Ankylosing Spondylitis (AS) Using Smart System of Disease Management (SSDM): Analysis of T2T Pattern Shift and Influential Factors
Background/Purpose: This study is to evaluate pattern shifts and outcome trends of treat-to-target (T2T) under standard of care in ankylosing spondylitis (AS) patients with interactive…Abstract Number: 2513 • 2017 ACR/ARHP Annual Meeting
The Effect of Alcohol on Disease Activity in Axial Spondyloarthritis
Background/Purpose: There has been much interest in smoking as a modifiable risk factor for increased disease severity in rheumatic diseases. However, the effects of alcohol…Abstract Number: 2893 • 2017 ACR/ARHP Annual Meeting
The Use of Natural Language Processing to Identify, Retrieve, Report, and Correct Observational Data on US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
Background/Purpose: The Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry is an observational cohort study at 12 VA medical centers that prospectively collects clinical…Abstract Number: 579 • 2017 ACR/ARHP Annual Meeting
Circulating MiR-145 As a Marker of Therapeutic Response to Anti-TNF Therapy in Patients with Ankylosing Spondylitis
Background/Purpose: The altered expression of miRNAs contributes to the pathophysiology of inflammatory conditions. In addition, circulating miRNAs may serve as promising therapeutic and prognostic biomarkers.…Abstract Number: 1065 • 2017 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T Cell Deficiency in Systemic Lupus Erythematosus Is Realted to an Intrinsic Defect in the Ca2+/Calcineurin/NFAT1 Signaling Pathway
Background/Purpose: Mucosal-associated invariant T (MAIT) cells contribute to protection against certain microorganism infections and play an important role in mucosal immunity. However, the role of…Abstract Number: 1461 • 2017 ACR/ARHP Annual Meeting
The Relationship between Serum IL-37 and Disease Activity in Patients with Rheumatoid Arthritis: Post-Hoc Analysis of Planetra Study
The relationship between serum IL-37 and disease activity in patients with rheumatoid arthritis: post-hoc analysis of PLANETRA study. Background/Purpose: Rheumatoid Arthritis (RA) is a chronic…Abstract Number: 1802 • 2017 ACR/ARHP Annual Meeting
Detection of Flare over the Past 3 Months in Rheumatoid Arthritis: Cross-Cultural Equivalence of the Self-Report Flare-RA Questionnaire
Background/Purpose: The Flare-RA questionnaire was developed and validated in French (1) for assessing the occurrence of a flare of rheumatoid arthritis (RA) during a 3-month…Abstract Number: 2242 • 2017 ACR/ARHP Annual Meeting
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Background/Purpose: Treat-to-Target (T2T), achieving a DAS28 lower than 2.6 (remission) or below 3.2 (low disease activity), is the main management strategy. The Smart System of…Abstract Number: 2521 • 2017 ACR/ARHP Annual Meeting
Metabolic Syndrome Is Associated with Active Disease in Psoriatic Arthritis and May Contribute to Development of Syndesmophytes
Background/Purpose: An increased prevalence of metabolic syndrome (MetS) has been reported in psoriatic arthritis (PsA) suggesting an association between the inflammation and MetS. The aim…Abstract Number: 2903 • 2017 ACR/ARHP Annual Meeting
Serum CC-Chemokine Ligand 18 Level Is a Potential Biomarker of Disease Activity in IgG4-Related Disease
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic disorder characterized by severe fibrosis in lesions. In previous reports, CC-chemokine ligand 18 (CCL18) level is a substantial…Abstract Number: 622 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Background/Purpose: Very low disease activity (VLDA) or remission (REM) and alternatively, minimal disease activity (MDA) or low disease activity (LDA) are optimal targets to be…Abstract Number: 1078 • 2017 ACR/ARHP Annual Meeting
Initial Combination Therapy Versus Step-up Therapy Is More Effective and Less Costly As a Treat to Target Strategy for RA: A Markov Model Based upon the Dutch Rheumatoid Arthritis Monitoring Registry Cohorts
Background/Purpose: Adjusting medication of patients with rheumatoid arthritis (RA) until predefined disease activity targets are met, i.e. Treat to Target (T2T), is the currently recommended…Abstract Number: 1474 • 2017 ACR/ARHP Annual Meeting
A Higher DAS28P, the Subjective Proportion of the DAS28, Predicts a Favorable Response to Abatacept in Rheumatoid Arthritis
Background/Purpose: Response prediction of certain biologic agents for the treatment of rheumatoid arthritis (RA) is still an unmet need in real-world clinical practice. To reduce…Abstract Number: 1806 • 2017 ACR/ARHP Annual Meeting
Performance of the Brief Index of Lupus Damage (BILD) in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort
Background/Purpose: The BILD1,2 was developed and validated as a measure of SLE organ damage for use in epidemiologic studies in which administration of the SLICC…Abstract Number: 2263 • 2017 ACR/ARHP Annual Meeting
Obesity Independently Associates with Worse Patient Reported Outcomes in Women with Systemic Lupus Erythematosus
Background/Purpose: Obesity has been shown to exacerbate systemic inflammation in the general population and contributes to worse disease-related outcomes in rheumatoid arthritis. The impact of…
- « Previous Page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- …
- 102
- Next Page »